EA200500533A1 - Пептидные производные - ингибиторы слияния при вич-инфекции - Google Patents

Пептидные производные - ингибиторы слияния при вич-инфекции

Info

Publication number
EA200500533A1
EA200500533A1 EA200500533A EA200500533A EA200500533A1 EA 200500533 A1 EA200500533 A1 EA 200500533A1 EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A1 EA200500533 A1 EA 200500533A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
mercury
hiv infection
peptide derivatives
derivatives
Prior art date
Application number
EA200500533A
Other languages
English (en)
Other versions
EA007918B1 (ru
Inventor
Донг Ксай
Хе Джанг
Original Assignee
Франтиэ Биотекнолоджиз Ко., Лтд.
Жиан, Хи
Донг Ксай
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Франтиэ Биотекнолоджиз Ко., Лтд., Жиан, Хи, Донг Ксай filed Critical Франтиэ Биотекнолоджиз Ко., Лтд.
Publication of EA200500533A1 publication Critical patent/EA200500533A1/ru
Publication of EA007918B1 publication Critical patent/EA007918B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к производным gp41-пептидов, которые представляют собой ингибиторы вирусной инфекции и/или обладают антифузогенными свойствами. В частности, данное изобретение относится к производным gp41-пептидов, обладающим ингибирующим действием по отношению к вирусу иммунодефицита человека (ВИЧ) и вирусу иммунодефицита обезьян (ВИО) и имеющим увеличенную продолжительность действия при лечении соответствующих вирусных инфекций.Отчет о международном поиске был опубликован 2004.08.12.
EA200500533A 2002-09-24 2003-09-23 Пептидные производные-ингибиторы слияния при вич-инфекции EA007918B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24
PCT/US2003/029815 WO2004029201A2 (en) 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of hiv infection

Publications (2)

Publication Number Publication Date
EA200500533A1 true EA200500533A1 (ru) 2005-12-29
EA007918B1 EA007918B1 (ru) 2007-02-27

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500533A EA007918B1 (ru) 2002-09-24 2003-09-23 Пептидные производные-ингибиторы слияния при вич-инфекции

Country Status (15)

Country Link
US (3) US7575750B2 (ru)
EP (1) EP1542718B1 (ru)
JP (2) JP5385497B2 (ru)
CN (1) CN1327897C (ru)
AP (1) AP2203A (ru)
AU (2) AU2003275116A1 (ru)
BR (1) BR0314657A (ru)
CA (1) CA2500248C (ru)
CR (1) CR7806A (ru)
EA (1) EA007918B1 (ru)
ES (1) ES2558680T3 (ru)
IL (1) IL167527A (ru)
NZ (1) NZ539539A (ru)
WO (1) WO2004029201A2 (ru)
ZA (1) ZA200503118B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741453B2 (en) 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
NZ539539A (en) * 2002-09-24 2006-11-30 Frontier Biotechnologies Co HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
CN114306225A (zh) * 2019-05-07 2022-04-12 前沿生物药业(南京)股份有限公司 稳定的艾博韦泰组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
AU723537B2 (en) * 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AU764103B2 (en) * 1999-05-17 2003-08-07 Conjuchem Biotechnologies Inc. Long lasting anti-angiogenic peptides
EP1591453A1 (en) * 1999-05-17 2005-11-02 ConjuChem Inc. Modified peptides yy and conjugates thereof
AU761591B2 (en) * 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
EA003922B1 (ru) * 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
NZ539539A (en) * 2002-09-24 2006-11-30 Frontier Biotechnologies Co HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties

Also Published As

Publication number Publication date
JP2006505536A (ja) 2006-02-16
ZA200503118B (en) 2006-11-29
BR0314657A (pt) 2005-08-02
US7575750B2 (en) 2009-08-18
JP2010209097A (ja) 2010-09-24
EP1542718A2 (en) 2005-06-22
NZ539539A (en) 2006-11-30
AU2003275116A1 (en) 2004-04-19
US20140187476A1 (en) 2014-07-03
IL167527A (en) 2013-12-31
US8470527B2 (en) 2013-06-25
AU2010200823B2 (en) 2011-12-15
ES2558680T3 (es) 2016-02-08
AP2005003291A0 (en) 2005-06-30
AU2010200823A1 (en) 2010-03-25
WO2004029201A2 (en) 2004-04-08
CA2500248A1 (en) 2004-04-08
US20050089840A1 (en) 2005-04-28
CN1327897C (zh) 2007-07-25
CN1668330A (zh) 2005-09-14
CR7806A (es) 2007-09-07
EP1542718A4 (en) 2011-04-06
AP2203A (en) 2011-01-31
US20110003735A1 (en) 2011-01-06
EA007918B1 (ru) 2007-02-27
EP1542718B1 (en) 2015-11-11
CA2500248C (en) 2013-03-19
JP5385497B2 (ja) 2014-01-08
WO2004029201A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
IS7532A (is) Heterósýklískir súlfónamíð lifrarbólgu C-veirutálmar
EA200700243A1 (ru) Способы лечения гепатита с
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
DE60336550D1 (de) Inhibitoren des hepatitis-c-virus
CY1108036T1 (el) Κυτταρικη συσσωρευση φωσφονικων αναλογων ενωσεων αναστολεα πρωτεασης του ιου ανοσολογικης ανεπαρκειας του ανθρωπου (hiv) και οι ενωσεις ως τετοιες
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
EA199700222A1 (ru) Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
DE60130641D1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
WO2007002172A3 (en) Hiv-1 protease inhibitors
MX9700414A (es) Agentes antivirales de difluoroestatona.
WO2003052122A3 (en) Gp41 inhibitor
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
EA200401611A1 (ru) Пептиды gp41 и способы ингибирования слияния вич с клетками-мишенями на их основе
WO2005060541A3 (en) Peptides and methods for inducing cellular resistance to infection
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU